Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Hematology, Anemia, Chemotherapy, Darbepoetin alfa, Erythropoietin-stimulating agents, Non-Hodgkin lymphoma, ERYTHROPOIESIS-STIMULATING AGENTS, EORTC GUIDELINES, ELDERLY-PATIENTS, STUDY-LEVEL, CANCER, METAANALYSIS, PROTEINS, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin, Drug Administration Schedule, Erythropoietin, Female, Hematinics, Humans, Lymphoma, Non-Hodgkin, Male, Middle Aged, Prednisolone, Rituximab, Treatment Outcome, Vincristine, 1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences, Immunology, 3201 Cardiovascular medicine and haematology

Abstract:

IMPACT NHL was a multicenter, observational study in adults with non-Hodgkin lymphoma receiving CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy with or without rituximab. Erythropoietin-stimulating agent treatment was given according to routine clinical practice and physician preference. In a subanalysis, outcomes were evaluated in 207 patients who received darbepoetin alfa (DA). The most common reason (81%) for initiating DA was low/declining hemoglobin (Hb) concentration. Mean (±standard deviation) duration of DA exposure was 8.8 ± 6.9 weeks (mean number of doses, 5.1 ± 4.6). Overall, 23% of patients had chemotherapy and DA treatment synchronized more than 75% of the time. At the time of DA initiation, 67% of patients had Hb concentrations in the guideline-recommended range (9-11 g/dl). Of 89 patients with Hb concentrations <10 g/dl at DA initiation and still receiving DA 5 weeks later, 92% (Kaplan-Meier) achieved Hb concentrations 10-12 g/dl between week 5 and at the end of treatment.